Granules India Ltd Corporate Actions

LIC Increases Stake in Granules India to 5.02%

 Copy Link

The pharma company caters to various international markets, reinforcing its position as a key player in the pharmaceutical industry.

Granules India’s Gagillapur Facility Receives USFDA Warning Letter

 Copy Link

Granules India, maintaining that it fully intends to respond in the time period allowed, as well as requesting a meeting with the FDA to show progress made in compliance, has taken care to make this clear as well.

Granules India Secures USFDA Approval for Andhra Facility

 Copy Link

The inspection covered Active Pharmaceutical Ingredients (APIs) and Finished Dosages (FDs) for oncology and non-oncology segments, underscoring the plant’s adherence to high manufacturing standards.

Granules India Secures USFDA Nod for Bupropion SR Tablets

 Copy Link

Bupropion hydrochloride is widely prescribed for treating major depressive disorder (MDD) and preventing seasonal affective disorder (SAD).

Granules India’s Gagilapur unit gets 6 observations from USFDA

 Copy Link

The USFDA has also noted a repeat observation from the company's January 2023 inspection.

Granules India Gets USFDA Nod for Pediatric Glycopyrrolate Oral Solution

 Copy Link

Glycopyrrolate Oral Solution is an anticholinergic medication used to treat pediatric patients aged 3 to 16 years with neurological conditions that cause drooling.